IceCure Medical's ProSense Featured at CIRSE 2025

Ticker: ICCM · Form: 6-K · Filed: Sep 22, 2025 · CIK: 1584371

Sentiment: neutral

Topics: medical-devices, clinical-results, press-release

TL;DR

IceCure Medical's ProSense system showed positive clinical results at CIRSE 2025 from 4 studies.

AI Summary

On September 22, 2025, IceCure Medical Ltd. announced that its ProSense system was featured at the CIRSE 2025 Annual Meeting. Four independent studies presented positive clinical results from cryoablation procedures using the ProSense device. The company is a foreign private issuer based in Israel.

Why It Matters

The presentation of positive clinical results at a major medical conference like CIRSE can enhance the company's reputation and potentially drive adoption of its cryoablation technology.

Risk Assessment

Risk Level: low — This filing is an informational report of a press release and does not contain significant financial or operational updates that would typically increase risk.

Key Players & Entities

FAQ

What specific clinical results were presented for the ProSense® system at CIRSE 2025?

The filing states that positive clinical results were presented, but does not provide specific data points or outcomes within this report.

How many independent studies presented data on the ProSense® system?

Four independent studies presented clinical results with cryoablation using the ProSense® system.

What is the primary purpose of this Form 6-K filing?

This Form 6-K is filed to report a press release issued by IceCure Medical Ltd. regarding the presentation of clinical results at the CIRSE 2025 Annual Meeting.

Where is IceCure Medical Ltd. headquartered?

IceCure Medical Ltd. is headquartered in Caesarea, Israel.

What is the Commission File Number for IceCure Medical Ltd.?

The Commission File Number for IceCure Medical Ltd. is 001-40753.

Filing Stats: 314 words · 1 min read · ~1 pages · Grade level 12.4 · Accepted 2025-09-22 08:35:16

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: September 22, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing